Terns Pharmaceuticals Secures Full Licensing Rights for Leukemia Drug TERN-701 from Hansoh Pharmaceutical

Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal | BioPharma Dive

===============

An article from

News roundup

Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal

==================================================================================

Prescriptions for oral Wegovy surged past 18,000 in its second full week. Elsewhere, Terns opened up room for a potential partnership and Corcept solidified its case for an ovarian cancer drug.

Published Jan. 23, 2026

By BioPharma Dive staff

Share
- Copy link
- Email
- LinkedIn
- X/Twitter
- Facebook
- Print
License
Add us on Google

Image 13: A stack of newspapers are seen against a blue background.

Getty Images

Today, a brief rundown of news from Novo Nordisk and Terns Pharmaceuticals, as well as updates from Corcept Therapeutics and BioMérieux that you may have missed.

Early numbers from Novo Nordisk’s launch of an oral form of Wegovycontinued to outpace expectations. According to analytics shared with Wall Street analysts, about 18,000 prescriptions were written for the week ending Jan. 16, a “very strong” figure following the roughly 3,000 issued the prior week, wrote Evercore ISI’s Umer Raffat. As with the previous total, the number didn’t include prescriptions through Novo’s online service and, notably at least so far, hasn’t come at the expense of the injectable Wegovy, Raffat noted. Novo shares ticked up another 2% and have climbed about 20% over the last month.— Ben Fidler

Terns Pharmaceuticals has amended the licensing deal surrounding its closely watched leukemia drug. According to a regulatory filing made public Thursday, Terns acquired from China’s Hansoh Pharmaceutical the ability to license the drug, known as TERN-701 and in testing for chronic myeloid leukemia, in territories where Hansoh doesn’t have rights. Under the terms of a 2020 deal, Hansoh had to clear other partnering decisions. But for a $1 million upfront payment and a small royalty, Terns can now seek other collaborations “without consent” from Hansoh, noted Mizuho Securities’ Graig Suvannavejh. The move should “clear the way for a potential partnership,” he added. TERN-701 is seen by some analysts as potentially disrupting the treatment landscape for CML.— Ben Fidler

Corcept Therapeuticssaid Thursday that an experimental treatment it’s developing helped extend survivalin a pivotal trial in ovarian cancer. A regimen involving the drug, relacorilant, and a kind of chemotherapy was associated with a 35% reduction in the risk of death compared to treatment with that chemotherapy alone.Corcept had previously revealed that the treatment met its other main goal in the study by meaningfully improving progression-free survival.The Food and Drug Administration in December rejected an application to approve relacorilant for a kind of hypertension. It’s set to make a decision on the drug’s use in ovarian cancer by July 11. Corcept shares climbed by double digits Thursday.— Delilah Alvarado

Keep up with the story. Subscribe to the BioPharma Dive free daily newsletter

Email:

Select Newsletter: - [x] Daily Dive M-F
Select Newsletter: - [x] Commercialization Weekly Every Wednesday
Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

French firm BioMérieuxhas acquired all of the rights it didn’t own in Accellix, a company that provides quality control assistance and helps speed up the manufacturing of cell therapies. BioMérieux has been collaborating with Accellix since 2020 and, prior to the acquisition, owned 10% of its stock. On Thursday, it agreed to pay 35 million euros, or about $41 million, to buy the rest of the company. The deal puts BioMérieux “at the forefront of innovation and quality control for advanced therapies,” which include cell and gene therapies, the company said in a statement. — Ben Fidler